Peter Buggisch

12.9k citations

192 papers · 4.9k indexed · h-index 29

Hepatology top 0.1%
- Hepatitis C virus research 153
- Liver Disease and Transplantation 15
- Liver Diseases and Immunity 15
Epidemiology top 0.5%
- Liver Disease Diagnosis and Treatment 103
- Hepatitis B Virus Studies 79
Infectious Diseases top 2%
- HIV/AIDS drug development and treatment 21
Oncology top 5%
Immunology top 5%
Rheumatology
- Systemic Lupus Erythematosus Research 28
Genetics
- Chronic Lymphocytic Leukemia Research 11

Co-authors: Thomas Berg Stefan Zeuzem Christoph Sarrazin Heiner Wedemeyer Wolff Schmiegel G. Riethmüller R. Raab H. Hirche
Cited by: Hepatology Epidemiology Infectious Diseases
Journals: Journal of Hepatology (69 papers)Liver International (10 papers)Hepatology (10 papers)
Partner nations: Germany United States France

In The Last Decade

Peter Buggisch

178 papers receiving 4.7k citations

Peers

Countries citing papers authored by Peter Buggisch

Since Specialization

Citations

This map shows the geographic impact of Peter Buggisch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Buggisch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Buggisch more than expected).

Fields of papers citing papers by Peter Buggisch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Buggisch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Buggisch. The network helps show where Peter Buggisch may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Peter Buggisch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Buggisch Line = papers co-authored together Peter Buggisch links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Metabolic Dysfunction–Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel Liver International ·Kazuhiro Sango,M. B. M. WEEMERS,ابن حدو وهيبة,Monu Mahan,Heike Bantel,Peter Buggisch,Andreas Geier,Wolf Peter Hofmann,Stefan Mauss,Elke Roeb,Jörn M. Schattenberg,Karl‐Georg Simon,Norbert Stefan,Katja Deterding,Johannes Wiegand,Anita Pathil,Frank Tacke	2025	3
2	Evaluating Resmetirom Eligibility Among Patients with MASH: Insights from the German Steatotic Liver Disease-Registry Zeitschrift für Gastroenterologie ·McLin Sari,David Petroff,Jörn M. Schattenberg,S Zeuzem,Manfred von der Ohe,Leopold Ludwig,Münevver Demir,Peter Buggisch,Kerstin Stein,杉山長毅,Heiner Wedemeyer,Thomas Berg,Wolf Peter Hofmann,J Bovenkerk,Johannes Wiegand	2025	1
3	195P Risk factors in patients with hepatocellular carcinoma: A German claims data analysis Annals of Oncology ·JAMAL DALEELURAHMAN,Karin Berger,冯爱军,Peter Buggisch,恵子吉松,誠加藤,Julia Mayerle,Sahar H. Orabi,Alexander Philipp,Kaiping Sun,Jörg Trojan,Enrico N. De Toni,Najib Ben Khaled	2024	1
4	Strategietreffen: Virushepatitis in Deutschland eliminieren – Was ist zu tun? Zeitschrift für Gastroenterologie ·Tammo Lambert Tergast,Ulrike Protzer,Stefan Zeuzem,О.Г. Римар,Christoph Sarrazin,Felix Frauendorfer,Patrick Ingiliz,Markus Cornberg,Ruth Zimmermann,Kuniyasu Takagi,Peter Buggisch,Jung Sang Woo,Heiner Wedemeyer	2023	0
5	Resolution of portal hypertension by insertion of a transjugular intrahepatic portosystemic shunt (TIPS) ameliorates markers of gut barrier function, systemic hyperinflammation and reverses phenotypic alterations of monocytes in patients with decompensated liver cirrhosis Zeitschrift für Gastroenterologie ·Felix Piecha,G. Moonen,Lívia Silva Santos,Ya-Nan Xu,Dawn Rosarie Orboc,Gustav Buescher,James W. Moyer,Daniel Benten,Christoph Riedel,Peter Buggisch,Peter Hübener,Samuel Huber,Ansgar W. Lohse,Peter Bannas,Lidia Bosurgi,Johannes Kluwe	2023	1
6	Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany – First data from the German NAFLD-Registry Zeitschrift für Gastroenterologie ·Andreas Geier,Monika Rau,Anita Pathil‐Warth,Manfred von der Ohe,Jörn M. Schattenberg,Nektarios Dikopoulos,Kerstin Stein,杉山長毅,Thomas Berg,Peter Buggisch,Münevver Demir,Elke Roeb,Jung Sang Woo,Heiner Wedemeyer,Stefan Zeuzem,Wolf Peter Hofmann	2023	4
7	Real‐world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R) Zeitschrift für Gastroenterologie ·Weburn,S. Rossol,Christian Krauth,Peter Buggisch,Stefan Mauss,Albrecht Stoehr,Hartwig Klinker,Klaus H.W. Böker,G Teuber,Jona T. Stahmeyer	2022	3
8	Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe Journal of Viral Hepatitis ·P. Cacoub,Peter Buggisch,J.A. Carrión,May Baniyas,Anna Linda Zignego,Rachel Beckerman,Zobair M. Younossi	2018	22
9	Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response PLoS ONE ·Tarik Asselah,Christophe Moreno,Christoph Sarrazin,Michael Gschwantler,Graham R. Foster,Antonio Craxı̀,Peter Buggisch,Faisal M. Sanai,Gloria Yeni García Lizcano,Oliver Lenz,I. E. Shinkarkin,孝通平山,Isabelle Lonjon‐Domanec,Michael Schlag,Marı́a Buti	2017	6
10	Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials Liver International ·Frank Tacke,Rainer Günther,Peter Buggisch,Hartwig Klinker,Andreas Schober,Debasis S. N Das,Thomas A. Lutz,Kamal Rashmawi,Claus Niederau,Markus Cornberg,Christoph Sarrazin,Stefan Mauss	2016	30
11	Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1 Journal of Gastrointestinal and Liver Diseases ·Tim Zimmermann,D. Hueppe,Stefan Mauss,Peter Buggisch,Kamal Rashmawi,Daniela Grimm,Peter R. Galle,U. Alshüth	2016	4
12	Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA PLoS ONE ·Benjamin Heidrich,Steffen B. Wiegand,Peter Buggisch,Holger Hinrichsen,Я.С. Карпов,Bernd Möller,Klaus H.W. Böker,G Teuber,Hartwig Klinker,E Zehnter,S.J. Watson-Jones,Raffi Fairuza Tertiano,Benjamin Maasoumy,Tabassumut Tasfia,Svenja Hardtke,Michael P. Manns,Heiner Wedemeyer,Jörg Petersen,Markus Cornberg,(unknown)	2014	13
13	Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions Journal of Hepatology ·David M. Burger,David Back,Peter Buggisch,Marı́a Buti,Antonio Craxı̀,Graham R. Foster,Hartwig Klinker,Dominique Larrey,И. Г. Никитин,Stanislas Pol,Massimo Puoti,Manuel Romero‐Gómez,Heiner Wedemeyer,Stefan Zeuzem	2012	91
14	Hepatitis D virus‐specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa‐treatment Liver International ·Jan Grabowski,Cihan Yurdaydın,Kalliopi Zachou,Peter Buggisch,Wolf Peter Hofmann,Jerzy Jaroszewicz,Verena Schlaphoff,Michael P. Manns,Markus Cornberg,Heiner Wedemeyer,(unknown)	2011	39
15	Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks Gastroenterology ·Christoph Sarrazin,Susanne Schwendy,Bernd Möller,Nektarios Dikopoulos,Peter Buggisch,Jens Encke,G Teuber,Tobias Goeser,Robert Thimme,Hartwig Klinker,Wulf O. Boecher,Ewert Schulte‐Frohlinde,Karen Lewis,Eva Herrmann,Stefan Zeuzem,Thomas Berg	2011	34
16	73 A MULTICENTER ANALYSIS OF ANTIVIRAL RESPONSE AFTER ONE YEAR OF TENOFOVIR MONO-THERAPY IN HBV-MONOINFECTED PATIENTS WITH PRIOR NUCLEOS(T)IDE ANALOG EXPERIENCE Journal of Hepatology ·Kalyane S Ávila,Robert A. de Man,Kerstin Stein,Narjol Gonzalez-Escalona,J. Petersen,Peter Buggisch,H. Wedemeyer,C. Sarrazin,Jörg Trojan,E Ekedigwe,Andreas Erhardt,Ulrich Spengler,Jurriën G.P. Reijnders,Robert T. SCHIMKEt,Doğukan Balta,Bertram Wiedenmann,Thomas Berg	2008	18
17	[636] THE INFLUENCE OF NUCLEOSIDE FREE HAART ON THE TREATMENT OF CHRONIC HEPATITIS C WITH PEGYLATED INTERFERON/RIBAVIRIN COMBINATION TREATMENT Journal of Hepatology ·Jürgen K. Rockstroh,H. Callihan,M. Vogel,Gerd Klausen,Thomas A. Lutz,Dirk Schuermann,Amina Carlebach,Christoph Mayr,Chia-Ling Yang,Peter Buggisch,W. Ded Dillinger,C John,Jeff Wuenschell,S Staszewski	2007	1
18	508 48 Weeks of adefovir mono therapy following 48 weeks of combination therapy with peginterferon alpha-2b and adefovir leads to additional biochemical and virological improvement Journal of Hepatology ·Marc Lütgehetmann,Karsten Wursthorn,Peter Buggisch,Bernhard Zöllner,M Zankel,C Fischer,Carol Brosgart,J. Petersen	2006	1
19	Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin Gastroenterology ·Thomas Berg,Michael Wagner,Samer Nasser,Christoph Sarrazin,Tobias Heintges,Tilman Gerlach,Peter Buggisch,Tobias Goeser,J. Rasenack,Gerd R. Pape,Wolfgang E. Schmidt,B. Kallinowski,Hartwig Klinker,Ulrich Spengler,Peter Martus,U. Alshüth,Stefan Zeuzem	2006	368
20	Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ). Gastroenterology ·Marion G. Peters,Hie‐Won Hann,Paul Martin,E. Jenny Heathcote,Peter Buggisch,R Rubin,Marc Bourlière,Kris V. Kowdley,Christian Trépo,DF Gray,Mark Sullivan,K. Kleber,Ramin Ebrahimi,S. Xiong,Carol Brosgart	2003	440

About Peter Buggisch

Peter Buggisch is a scholar working on Hepatology, Epidemiology and Rheumatology, having authored 192 papers that have together received 4.9k indexed citations. Recurring topics across this work include Hepatitis C virus research (153 papers), Liver Disease Diagnosis and Treatment (103 papers), Hepatitis B Virus Studies (79 papers), Systemic Lupus Erythematosus Research (28 papers), HIV/AIDS drug development and treatment (21 papers), Liver Disease and Transplantation (15 papers), Liver Diseases and Immunity (15 papers) and Chronic Lymphocytic Leukemia Research (11 papers). The work is most often cited by research in Hepatology (3.4k citations), Epidemiology (3.3k citations) and Infectious Diseases (586 citations). Peter Buggisch has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Thomas Berg, Stefan Zeuzem, Christoph Sarrazin, Heiner Wedemeyer, Wolff Schmiegel, G. Riethmüller, R. Raab, H. Hirche, K. Höffken and R. Pichlmayr. Their work appears in journals such as Journal of Hepatology, Liver International, Hepatology, Gastroenterology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact